Drug intelligence / Profile preview

HZBio2

Development stage: Unknown
Lead developer: Hangzhou Grand Biologic Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

HZBio2 is a biosimilar candidate of vedolizumab, a humanized monoclonal antibody. It is developed by Hangzhou Yuanda Biopharmaceutical for the treatment of inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. Like the reference product, HZBio2 binds to the human α4β7 integrin, a glycoprotein expressed on the surface of a subset of gastrointestinal-homing T lymphocytes. By blocking the interaction of α4β7 with mucosal addressin cell adhesion molecule-1 (MAdCAM-1), it inhibits the migration of these inflammatory cells into the gastrointestinal mucosa, thereby reducing inflammation.

Other names: vedolizumab biosimilar

Targets

α4β7 (Integrin alpha-4 beta-7 heterodimer)

Beyond the preview

Go deeper on HZBio2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HZBio2.

Explore the full profile